All In Biotech

Drug Trial Radar · NCT01421498

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)

Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 588 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

588

Actual

Start

Aug 29, 2011

Primary completion

Apr 28, 2012

Study completion Apr 28, 2012

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Aug 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID for 12 weeks will also be evaluated.

Conditions

  • Keratoconjunctivitis Sicca
  • Dry Eye Disease

Interventions

  • LifitegrastDrug

    Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks

  • PlaceboDrug

    Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84Time frame: Baseline (Day 0) to Day 84
  2. Ocular Symptom: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84Time frame: Baseline (Day 0) to Day 84

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • OPUS-1 Investigational Site

    Waterbury, Connecticut

  • OPUS-1 Investigational Site

    Louisville, Kentucky

  • OPUS-1 Investigational Site

    Augusta, Maine

  • OPUS-1 Investigational Site

    Lewiston, Maine

  • OPUS-1 Investigational Site

    Andover, Massachusetts

  • OPUS-1 Investigational Site

    Lancaster, Massachusetts

  • OPUS-1 Investigational Site

    Quincy, Massachusetts

  • OPUS-1 Investigational Site

    Wakefield, Massachusetts

  • OPUS-1 Investigational Site

    Winchester, Massachusetts

  • OPUS-1 Investigational Site

    Derry, New Hampshire

  • OPUS-1 Investigational Site

    Manchester, New Hampshire

  • OPUS-1 Investigational Site

    Memphis, Tennessee

  • OPUS-1 Investigational Site

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.